Leucettinib-21 decreases dosage effects of DYRK1A in human trisomy 21 induced pluripotent stem cell-derived neural cells
Disease Models & Mechanisms · 2026
DOI: 10.1242/dmm.052740 ↗Kurz gefasst
Fachartikel in der Zeitschrift Disease Models & Mechanisms, 2026. Verfasst von Nicole R West und 6 weiteren Autor:innen. Beteiligte Einrichtung: Waisman Center, University of Wisconsin-Madison, Madison, WI, USA. Hauptthemen laut MEDLINE: Protein Serine-Threonine Kinases, Protein-Tyrosine Kinases, Down Syndrome, Induced Pluripotent Stem Cells. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Child Health and Human Development, Bpifrance, NICHD NIH HHS.
Abstract (Originalsprache)
Dosage imbalance of dual specificity tyrosine phosphorylation regulated kinase 1A (DYRK1A) is a feature of several neurodevelopmental and neurodegenerative diseases, including Down syndrome, DYRK1A syndrome, autism spectrum disorders, Alzheimer's disease and Parkinson's disease. Thus, manipulating DYRK1A activity in the brain has emerged as a potential therapeutic target for neurological disorders. Several DYRK1A inhibitors have shown promise for improving cognition in rodent models of Down syndrome and Alzheimer's disease, for example, but the ability of these inhibitors to affect DYRK1A levels or activity in relevant human cells has not been established. We filled this gap by testing the effects of a new DYRK1A inhibitor on trisomy 21 induced pluripotent stem cell (iPSC)-derived neural progenitor cells and neurons, in which DYRK1A expression and activity are increased. Our results demonstrated that Leucettinib-21, a potent and selective low-molecular-mass pharmacological inhibitor of DYRK1A, decreases DYRK1A activity in human trisomy 21 iPSC-derived neural progenitor cells and cortical neurons. Leucettinib-21 reduces DYRK1A activity in a relevant human disease model, supporting future human trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Waisman Center, University of Wisconsin-Madison, Madison, WI, USA.
- Cellular and Molecular Biology Graduate Program, University of Wisconsin-Madison, Madison WI 53706, USA.
- Perha Pharmaceuticals, Perharidy Peninsula, 29680 Roscoff, France.
- Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, UMR 8601 CNRS, Université Paris Cité, Paris 75270, France.
- Department of Cell and Regenerative Biology, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53705, USA.
ORCID-Profile: Nicole R West, Anita Bhattacharyya
Förderung
- National Institute of Child Health and Human Development
- Bpifrance
- NICHD NIH HHS
- HORIZON EUROPE European Innovation Council
- Agence Nationale de la Recherche
- School of Medicine and Public Health, University of Wisconsin-Madison
- Fondation Jérôme Lejeune
- Wisconsin Alumni Research Foundation
Zitieren
APA
West, N. R., Lindberg, M. F., Dairou, J., MacGregor, S., Puthireddy, S., Meijer, L., & Bhattacharyya, A. (2026). Leucettinib-21 decreases dosage effects of DYRK1A in human trisomy 21 induced pluripotent stem cell-derived neural cells. Disease Models & Mechanisms. https://doi.org/10.1242/dmm.052740
Vancouver
West NR, Lindberg MF, Dairou J, MacGregor S, Puthireddy S, Meijer L, et al. Leucettinib-21 decreases dosage effects of DYRK1A in human trisomy 21 induced pluripotent stem cell-derived neural cells. Disease Models & Mechanisms. 2026. doi:10.1242/dmm.052740
BibTeX
@article{West2026,
author = {West, Nicole R and Lindberg, Mattias F and Dairou, Julien and MacGregor, Shawn and Puthireddy, Sahith and Meijer, Laurent and Bhattacharyya, Anita},
title = {Leucettinib-21 decreases dosage effects of DYRK1A in human trisomy 21 induced pluripotent stem cell-derived neural cells},
journal = {Disease Models & Mechanisms},
year = {2026},
doi = {10.1242/dmm.052740}
}
EUVIMED